Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

Latanoprost for hair loss is available in Canada at Ford's Family Pharmacy in New Brunswick, with up to 0.03% concentration, six times stronger than glaucoma medication Xalatan.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The conversation is about hair loss treatments, specifically mentioning finasteride, minoxidil, and the possibility of a hair transplant in Turkey. Users share humorous reactions and personal experiences with these treatments.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.

Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Bryan Johnson's new hair loss product, which includes peptides, is viewed skeptically by many, with concerns it may be a money grab rather than an effective treatment. Most users prefer proven treatments like finasteride and minoxidil, which are cheaper and have established results.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.